幽门螺杆菌
胃炎
药品
菌群(微生物学)
机制(生物学)
细菌
化学
药理学
医学
胃肠病学
生物
遗传学
认识论
哲学
作者
Elham Ghobadi,Zahra Ghanbarimasir,Saeed Emami
标识
DOI:10.1016/j.ejmech.2021.113669
摘要
Helicobacter pylori is one of the main causal risk factor in the generation of chronic gastritis, gastroduodenal ulcers and gastric carcinoma. Thus, the eradication of H. pylori infection is an important way for preventing and managing the gastric diseases. Multiple-therapy with several antibacterial agents is used for the eradication of H. pylori infections; however the increase of resistance to H. pylori strains has resulted in unsatisfactory eradication and unsuccessful treatment. Furthermore, the combination therapy with high dosing leads to the disruption of intestinal microbial flora and undesired side effects. Therefore, the search for new therapeutic agents with high selectivity against H. pylori is a field of current interest. In recent years, diverse compounds originating from natural sources or synthetic drug design programs were evaluated and tried to optimize for applying against H. pylori. In this review, we have described various classes of anti-H. pylori compounds, their structure-activity relationship studies, and mechanism of actions, which could be useful for the development of new drugs for the treatment of H. pylori infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI